Extended Data Confirms Acoramidis Sustains Cardiovascular Benefits, Reduces ACM at 36 Months
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced positive interim results from the ATTRibute-CM open-label extension (OLE) study of acoramidis, presented at the American…
Alnylam Reports Phase 1 Data: Nucresiran Shows Rapid, Sustained TTR Knockdown After One Dose
Alnylam Pharmaceuticals (Nasdaq: ALNY) presented encouraging Phase 1 results for nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic for transthyretin (ATTR) amyloidosis, at the American Heart Association Scientific Sessions 2024 in…
WHO and Partners Unite in Efforts to Eliminate Cervical Cancer
As world leaders gather in Rio de Janeiro, Brazil, for the G20 Summit this weekend, the city’s iconic Christ the Redeemer statue will be bathed in teal light in a…
Merck Receives Positive EU CHMP Opinion for KEYTRUDA
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) Merck (NYSE: MRK), known as MSD outside…
Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer
Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished…
Equillium reports Q3 2024 financial results and shares corporate and clinical updates
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel…
Americans Continue to Struggle to Access Branded GLP-1s as Shortages Continue
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access…
Lumicell’s Board of Directors Appoints Howard Hechler as Chief Executive Officer
Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is proud to announce the appointment of Howard Hechler as Chief…
AstraZeneca invests $3.5 billion in U.S. R&D and production
AstraZeneca today announced a $3.5 billion investment in the United States to expand the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion in new…
QPS Launches New Leukopak and Cell Therapy Products Facility
QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak…
TRexBio secures $84 million in Series B funding to advance its first-in-class immunology programs into clinical trials
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create…
Leaders gather at the Milken Institute 2024 Future of Health Summit to address global health issues
Business Leaders and Industry Experts Join Top Policymakers to Address Pivotal Issues in Health Globally at the Milken Institute 2024 Future of Health Summit The Milken Institute 2024 Future of Health…